
COPD: A Public Health Priority


Senior industry leaders shared their insights
Chronic obstructive pulmonary disease (COPD) has risen to become the third leading cause of death worldwide and is underfunded, under-prioritised and undertreated. Despite its prevalence and considerable cost to healthcare systems, COPD is relatively unknown by both the public and policymakers. A lack of understanding, misperceptions and negative bias surrounding COPD impacts timely and quality care for people with the disease. More severe COPD, meanwhile, is associated with higher healthcare utilisation, placing strains on already overstretched healthcare budgets. Better ways are urgently needed to address the significant burden that COPD places on both patients, carers and society.
The Financial Times, in partnership with AstraZeneca was honoured to host this exclusive virtual webinar for stakeholders in the global respiratory community and for those impacted by or engaged in the care of patients with COPD. Join an esteemed panel of health policymakers, leading clinicians and patient representatives as they discuss the path forward for improving respiratory strategies across governments, with sustainable and measurable impacts for patients.
Burden
What is the burden of COPD for patients and for healthcare systems?
Impact
What has the impact of COVID-19 been on the care of respiratory diseases?
Science
How is the science, and our knowledge and understanding of COPD progressing?
Why Watch?

Understand
The big picture, not just the individual strands of the business you work in

Connect
And build relationships with some of the biggest names in your industry

Discover
New approaches and strategies to COPD progressing
Now Available On-Demand
FT Live Digital Dialogues - fully digital one hour event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days.
We’re here to help
Disclaimer: This activity is wholly funded by AstraZeneca. AstraZeneca is involved in and responsible for the development of content related to this activity.
Z4-39027 | October 2021
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice